These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 33972578)

  • 21. The improved anticancer effects of Bortezomib-loaded hollow mesoporous silica nanospheres on lymphoma development.
    Shen J; Wang R; Wang Q; Zhang M; Liu C; Tao Z; Su G
    Aging (Albany NY); 2020 Dec; 13(1):411-423. PubMed ID: 33290262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Lipoic Acid on the Biochemical Mechanisms of Resistance to Bortezomib in SH-SY5Y Neuroblastoma Cells.
    Tibullo D; Giallongo C; Puglisi F; Tomassoni D; Camiolo G; Cristaldi M; Brundo MV; Anfuso CD; Lupo G; Stampone T; Li Volti G; Amenta F; Avola R; Bramanti V
    Mol Neurobiol; 2018 Apr; 55(4):3344-3350. PubMed ID: 28497200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of bortezomib-adapted I-45 mesothelioma cells.
    Zhang L; Littlejohn JE; Cui Y; Cao X; Peddaboina C; Smythe WR
    Mol Cancer; 2010 May; 9():110. PubMed ID: 20482802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ATF4 destabilizes RET through nonclassical GRP78 inhibition to enhance chemosensitivity to bortezomib in human osteosarcoma.
    Luo J; Xia Y; Yin Y; Luo J; Liu M; Zhang H; Zhang C; Zhao Y; Yang L; Kong L
    Theranostics; 2019; 9(21):6334-6353. PubMed ID: 31534554
    [No Abstract]   [Full Text] [Related]  

  • 25. Resistance to bortezomib in breast cancer cells that downregulate Bim through FOXA1 O-GlcNAcylation.
    Liu Y; Wang X; Zhu T; Zhang N; Wang L; Huang T; Cao Y; Li W; Zhang J
    J Cell Physiol; 2019 Aug; 234(10):17527-17537. PubMed ID: 30793308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity.
    Xiao G; Li Y; Wang Y; Zhao B; Zou Z; Hou S; Jia X; Liu X; Yao Y; Wan J; Xiong H
    Exp Cell Res; 2018 Sep; 370(2):254-263. PubMed ID: 29944867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.
    Baertsch MA; Mai EK; Hielscher T; Bertsch U; Salwender HJ; Munder M; Fuhrmann S; Dührsen U; Brossart P; Neben K; Schlenzka J; Kunz C; Raab MS; Hillengaß J; Jauch A; Seckinger A; Hose D; Luntz S; Sonneveld P; Lokhorst H; Martin H; Goerner M; Hoffmann M; Lindemann HW; Bernhard H; Blau IW; Scheid C; Besemer B; Weisel KC; Hänel M; Dürig J; Goldschmidt H;
    Blood Cancer J; 2021 Jan; 11(1):1. PubMed ID: 33414374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. B-Myb deficiency boosts bortezomib-induced immunogenic cell death in colorectal cancer.
    Hui YJ; Yu TT; Li LG; Peng XC; Di MJ; Liu H; Gu WL; Li TF; Zhao KL; Wang WX
    Sci Rep; 2024 Apr; 14(1):7733. PubMed ID: 38565963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe.
    Hu L; Li B; Chen G; Song D; Xu Z; Gao L; Xi M; Zhou J; Li L; Zhang H; Feng Q; Wang Y; Lu K; Lu Y; Bu W; Wang H; Wu X; Zhu W; Shi J
    J Exp Clin Cancer Res; 2020 Jun; 39(1):105. PubMed ID: 32517809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversal of bortezomib resistance in myelodysplastic syndrome cells by MAPK inhibitors.
    Yue Y; Wang Y; He Y; Yang S; Chen Z; Wang Y; Xing S; Shen C; Amin HM; Wu D; Song YH
    PLoS One; 2014; 9(3):e90992. PubMed ID: 24608798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance.
    Dolloff NG
    Adv Cancer Res; 2015; 127():191-226. PubMed ID: 26093901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity.
    Vaiou M; Pangou E; Liakos P; Sakellaridis N; Vassilopoulos G; Dimas K; Papandreou C
    J Cancer Res Clin Oncol; 2016 Oct; 142(10):2141-58. PubMed ID: 27530445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance.
    Wu YX; Yang JH; Saitsu H
    Oncotarget; 2016 Nov; 7(47):77622-77634. PubMed ID: 27769058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment.
    Li C; Hu J; Li W; Song G; Shen J
    Biomater Sci; 2016 Dec; 5(1):77-88. PubMed ID: 27822577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
    Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
    Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.
    Yin L; Kufe T; Avigan D; Kufe D
    Blood; 2014 May; 123(19):2997-3006. PubMed ID: 24632713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bortezomib-inducible long non-coding RNA myocardial infarction associated transcript is an oncogene in multiple myeloma that suppresses miR-29b.
    Fu Y; Liu X; Zhang F; Jiang S; Liu J; Luo Y
    Cell Death Dis; 2019 Apr; 10(4):319. PubMed ID: 30967527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bortezomib induces cellular senescence in A549 lung cancer cells by stimulating telomere shortening.
    Wang L; Yin H; Huang S; Huang S; Huang C; Zhang Z; Liu H
    Hum Exp Toxicol; 2022; 41():9603271221124094. PubMed ID: 36401358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
    Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
    Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy.
    Romano A; Parrinello NL; La Cava P; Tibullo D; Giallongo C; Camiolo G; Puglisi F; Parisi M; Pirosa MC; Martino E; Conticello C; Palumbo GA; Di Raimondo F
    Expert Rev Mol Diagn; 2018 Jul; 18(7):675-683. PubMed ID: 29707981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.